Physician profile
Jesse William Pace
NPI 1598027765
$2,573.28
in general payments reported to CMS, 2019-2025
23 companies · $1,113 in 2025
The $1,113 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $110 · 2023: $320 · 2024: $1,031 · 2025: $1,113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,463.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $417.25 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $320.74 | 2023-2025 | |
| Novo Nordisk INC | $293.64 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $234.98 | 2023-2025 | Mounjaro, Zepbound |
| Axsome Therapeutics, INC. | $232.57 | 2024-2025 | Auvelity |
| Glaxosmithkline, LLC. | $186.67 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $115.28 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $103.98 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $92.65 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $86.92 | 2023-2025 | Caplyta |
| Amgen INC. | $84.22 | 2022-2024 | Evenity, Prolia, Repatha |
| Vanda Pharmaceuticals INC. | $69.18 | 2024-2025 | Fanapt |
| Exact Sciences Corporation | $58.83 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Astellas Pharma US INC | $49.10 | 2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $45.49 | 2024-2025 | Trintellix |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $39.68 | 2022-2024 | Freestyle Libre 3 |
| Inari Medical, INC. | $34.22 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.81 | 2024 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $21.31 | 2025 | Rexulti |
| Corium, LLC | $16.44 | 2025 | Azstarys |
| Phathom Pharmaceuticals, INC. | $15.87 | 2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $15.73 | 2024 | Evkeeza |
| Baxter Healthcare | $14.72 | 2023 | Hillrom - Carnation Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Pace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.